EP Patent

EP3406608A1 — Therapeutically active compounds and their methods of use

Assigned to Les Laboratoires Servier SAS · Expires 2018-11-28 · 7y expired

What this patent protects

Provided are compounds being inhibitors of mutant IDH2 useful for treating cancer, methods for preparing such compounds and methods of treating cancer by administering to a subject in need thereof a compound described herein.

USPTO Abstract

Provided are compounds being inhibitors of mutant IDH2 useful for treating cancer, methods for preparing such compounds and methods of treating cancer by administering to a subject in need thereof a compound described herein.

Drugs covered by this patent

Patent Metadata

Patent number
EP3406608A1
Jurisdiction
EP
Classification
Expires
2018-11-28
Drug substance claim
No
Drug product claim
No
Assignee
Les Laboratoires Servier SAS
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.